Spots Global Cancer Trial Database for recurrent diffuse intrinsic pontine glioma

Every month we try and update this database with for recurrent diffuse intrinsic pontine glioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Combination Therapy for the Treatment of Diffuse Midline Gliomas	NCT05009992	Diffuse Intrins... Diffuse Midline... Recurrent Diffu... Recurrent Diffu... Recurrent WHO G... WHO Grade III G...	ONC201 Radiation Thera... Paxalisib	2 Years - 39 Years	University of California, San Francisco
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors	NCT03598244	Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim...	Biospecimen Col... Magnetic Resona... Savolitinib X-Ray Imaging	6 Years - 21 Years	National Cancer Institute (NCI)
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	NCT04870944	Diffuse Midline... Metastatic Mali... Recurrent Diffu... Recurrent Lymph... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Oste... Refractory Prim...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... FACT Complex-ta...	12 Months - 30 Years	Children's Oncology Group
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors	NCT03598244	Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim...	Biospecimen Col... Magnetic Resona... Savolitinib X-Ray Imaging	6 Years - 21 Years	National Cancer Institute (NCI)
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma	NCT02359565	Constitutional ... Lynch Syndrome Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Diffu... Recurrent Medul... Refractory Brai... Refractory Diff... Refractory Epen... Refractory Medu...	Biospecimen Col... Conventional Ma... Diffusion Tenso... Diffusion Weigh... Dynamic Contras... Dynamic Suscept... Magnetic Resona... Pembrolizumab	1 Year - 30 Years	National Cancer Institute (NCI)
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors	NCT05278208	High Grade Glio... Meningioma Embryonal Tumor Medulloblastoma Anaplastic Epen... Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim...	LUTATHERA® (Lut...	4 Years -	Nationwide Children's Hospital
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma	NCT04870944	Diffuse Midline... Metastatic Mali... Recurrent Diffu... Recurrent Lymph... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Oste... Refractory Prim...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... FACT Complex-ta...	12 Months - 30 Years	Children's Oncology Group

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: